Virtus LifeSci Biotech Clinical Trials ETF Rating $42.53 -0.61 (-1.41%) Closing price 11/13/2026 04:10 PM EasternExtended Trading$42.50 -0.02 (-0.06%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.78Holdings in BBC have an aggregate rating of Moderate Buy based on 301 analyst ratings issued in the past year covering 25 companies (33.5% of the portfolio).BBC Aggregate Price Target$42.53High Prediction$42.53Average Prediction$42.53Low Prediction$42.53Holdings in BBC have an aggregate price target of $42.53 and a range of $42.53 to $42.53 covering 25 companies (33.5% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold0 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings2.25%KODKodiak Sciences$111.19+2.7%Moderate Buy$109.00 -2.0%81.8707 of 5 starsNews CoverageEarnings ReportAnalyst Forecast2.24%XNCRXencor$37.09-2.7%Moderate Buy$42.22 13.8%112.1078 of 5 starsInsider Trade2.10%TRAXFirst Tracks Biotherapeutics$47.10-3.3%Moderate Buy$72.17 53.2%143.639 of 5 starsPositive News1.88%REPLReplimune Group$21.89-0.4%Moderate Buy$14.33 -34.5%101.4905 of 5 starsInsider Trade1.75%ABCLAbCellera Biologics$11.49-1.1%Moderate Buy$16.20 41.0%113.9546 of 5 starsTrending NewsEarnings ReportAnalyst ForecastInsider Trade1.56%AMLXAmylyx Pharmaceuticals$30.29+1.4%Buy$43.71 44.3%93.1164 of 5 starsNews CoverageAnalyst Forecast1.55%SGPSpyglass Pharma$32.88-1.3%Moderate Buy$45.83 39.4%93.3228 of 5 starsNews CoverageEarnings ReportAnalyst ForecastAnalyst Revision1.35%VRDNViridian Therapeutics$30.87+1.3%Moderate Buy$41.00 32.8%123.7355 of 5 stars1.30%PRMEPrime Medicine$4.27+9.8%Moderate Buy$7.86 84.0%93.5317 of 5 starsTrending NewsEarnings ReportGap Up1.25%PVLAPalvella Therapeutics$152.48-0.5%Buy$213.85 40.2%152.6811 of 5 starsNews CoverageInsider TradeAnalyst Revision1.18%KYMRKymera Therapeutics$127.57+0.3%Moderate Buy$139.16 9.1%272.0016 of 5 stars1.14%LBRXLB Pharmaceuticals$43.01+1.3%Moderate Buy$57.40 33.5%132.3912 of 5 starsAnalyst UpgradeAnalyst Revision1.14%ORKAOruka Therapeutics$105.35+0.3%Moderate Buy$141.80 34.6%102.8221 of 5 starsTrending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision1.12%MANEVeradermics$129.18-4.5%Moderate Buy$174.57 35.1%93.1 of 5 starsEarnings ReportAnalyst ForecastInsider Trade1.12%MBXMBX Biosciences$55.94+2.6%Moderate Buy$87.30 56.1%142.9834 of 5 starsTrending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision1.10%VIRVir Biotechnology$9.96-17.8%Moderate Buy$22.57 126.6%92.4245 of 5 starsTrending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading Volume1.10%ZBIOZenas BioPharma$28.01+1.3%Moderate Buy$46.71 66.8%93.2805 of 5 starsUpcoming EarningsAnalyst Revision1.10%MAZEMaze Therapeutics$34.33-4.9%Buy$65.50 90.8%132.7052 of 5 starsTrending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap Down1.07%FDMT4D Molecular Therapeutics$12.23+1.0%Moderate Buy$30.22 147.1%112.9502 of 5 starsNews CoverageEarnings ReportGap Down1.07%VORVor Biopharma$19.42+0.5%Buy$38.29 97.1%92.0448 of 5 stars1.05%SEPNSepterna$42.60+1.8%Moderate Buy$56.44 32.5%112.2849 of 5 starsTrending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision1.04%PCVXVaxcyte$63.37-2.0%Moderate Buy$110.50 74.4%93.1346 of 5 starsNews CoverageInsider Trade1.04%DFTXDefinium Therapeutics$32.08-2.8%Moderate Buy$66.24 106.5%213.1822 of 5 starsEarnings ReportAnalyst Forecast1.00%EWTXEdgewise Therapeutics$45.93+0.2%Moderate Buy$52.83 15.0%122.413 of 5 starsInsider TradeAnalyst Revision1.00%JANXJanux Therapeutics$11.37-1.0%Moderate Buy$36.92 224.7%162.8634 of 5 starsTrending NewsAnalyst DowngradeAnalyst Revision This page (NYSEARCA:BBC) was last updated on 11/15/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.